S-1 is administered orally at 80mg/m2/day for 14 consecuitive days followed by a 7 day rest. L-OHP is given intravenously on days 1, at adose of 130mg/m2/day. 21 days are assumed 1 course, and neoadju
Sponsors
Morohashi Hajime, Gastroenterological surgery, Hirosaki University
Conditions
locally advanced rectal cancerrectal cancer
rectal cancer
Phase 2
Phase II study of S-1 and L-OHP neoadjuvant chemotherapy with total mesorectal excision and lateral lymph node dissection for resectable rectal cancer (ACCS-01)
RecruitingJPRN-UMIN000019606
Start: 2015-11-01Target: 65Updated: 2026-06-29
Study of S-1 and L-OHP neoadjuvant chemotherapy with total mesorectal excision and lateral lymph node dissection
Active, not recruitingJPRN-jRCTs021180033
Start: 2015-11-01Target: 55Updated: 2026-06-29